The firm was appointed class counsel and certain generic manufacturers settled the claims against them.  On February 11, 2021, the United States District Court for the Southern District of New York issued an Opinion certifying a class of third-party payors that reimbursed insureds for the widely prescribed Alzheimer drug Namenda (Namenda IR and Namenda XR) and its generic equivalents in several states between June 1, 2012 and December 31, 2017.

This certification order relates to Plaintiff’s allegations that defendants Forest Laboratories (successor entities since acquired by AbbVie Inc.) and Merz Pharmaceuticals GmbH (and related entities) entered into several reverse payment settlements with generic manufacturers of Namenda to unlawfully delay the market entry of generic competitors.  To view the Class Notice, please check out Namenda Notice.